LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

LLY

1,005.07

+0.76%↑

JNJ

230.16

+1.55%↑

ABBV

212.68

+4.05%↑

UNH

396.89

-0.91%↓

AZN

185.26

+0.32%↑

Home・Elenco Azioni・Lantheus Holdings Inc

Lantheus Holdings Inc

Aperta

SettoreSettore sanitario

94.82 -2.31

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

94.9

Massimo

98.15

Metriche Chiave
By Trading Economics
Entrata	64M 118M
Vendite	-29M 377M
P/E Media del settore	22.451 51.415
EPS	1.46
Margine di Profitto	31.383
Dipendenti	1,193
EBITDA	-17M 81M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+7.3% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	410M 6.1B
Apertura precedente	97.13
Chiusura precedente	94.82

Notizie sul Sentiment di mercato

By Acuity

35%

65%

111 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

79.24 / 103.64 Supporto e resistenza

Lantheus Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 mag 2026, 22:54 UTC

Utili

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mag 2026, 23:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

13 mag 2026, 23:51 UTC

Discorsi di Mercato

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mag 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mag 2026, 23:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 mag 2026, 23:17 UTC

Utili

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mag 2026, 23:16 UTC

Utili

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mag 2026, 23:15 UTC

Utili

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mag 2026, 23:14 UTC

Utili

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mag 2026, 23:02 UTC

Discorsi di Mercato

Utili

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mag 2026, 22:59 UTC

Discorsi di Mercato

Utili

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mag 2026, 22:24 UTC

Utili

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mag 2026, 22:23 UTC

Utili

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mag 2026, 22:23 UTC

Utili

Xero FY International Revenue Growth 47%>XRO.AU

13 mag 2026, 22:22 UTC

Utili

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mag 2026, 22:19 UTC

Utili

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mag 2026, 22:19 UTC

Utili

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mag 2026, 22:18 UTC

Utili

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mag 2026, 22:16 UTC

Utili

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mag 2026, 22:15 UTC

Utili

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mag 2026, 22:15 UTC

Utili

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mag 2026, 22:13 UTC

Utili

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mag 2026, 22:12 UTC

Utili

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mag 2026, 22:11 UTC

Utili

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mag 2026, 22:11 UTC

Utili

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mag 2026, 22:10 UTC

Utili

Xero Did Not Declare a Dividend>XRO.AU

13 mag 2026, 22:10 UTC

Utili

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mag 2026, 22:09 UTC

Utili

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mag 2026, 22:00 UTC

Utili

Cisco to Shed Jobs for All-In AI Push -- Update

13 mag 2026, 21:11 UTC

Utili

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Lantheus Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

7.3% in crescita

Previsioni per 12 mesi

Media 103.25 USD 7.3%

Alto 115 USD

Basso 90 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lantheus Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Lantheus Holdings Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

79.24 / 103.64Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

111 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.